What is the appropriate vancomycin dosing for a 75‑kg patient with normal renal function (creatinine 0.7 mg/dL) who has a skin infection?

Vancomycin Dosing for Skin Infection in 75-kg Patient with Normal Renal Function

For a skin infection (uncomplicated SSTI), you should use lower-intensity vancomycin dosing targeting trough concentrations of 10-15 mg/L, which translates to approximately 15 mg/kg every 12 hours (1000-1125 mg every 12 hours) for this 75-kg patient with normal renal function.

Key Distinction: Infection Severity Determines Target Trough

The critical difference between skin infections and serious invasive infections (bacteremia, endocarditis, osteomyelitis, meningitis, hospital-acquired pneumonia) is the target trough concentration 1:

• Serious invasive S. aureus infections: Target trough 15-20 mg/L
• Uncomplicated skin infections: Target trough 10-15 mg/L (lower-intensity dosing)

The 2009 IDSA/ASHP/SIDP vancomycin guidelines explicitly state that "frequent monitoring for short-course therapy (≤5 days) or for lower-intensity dosing (targeted to attain trough serum vancomycin concentrations of ≤15 mg/L) is not recommended" 1. This directly applies to skin infections, which are typically short-course treatments.

Specific Dosing Recommendation

For your 75-kg patient with creatinine 0.7 mg/dL (indicating excellent renal function):

Initial dosing regimen:

• Dose: 15 mg/kg = 1125 mg (can round to 1000 mg for practical administration)
• Interval: Every 12 hours
• Infusion time: 1-1.5 hours (since dose is ≥1 g) 1

Rationale for This Approach

1. Weight-based dosing: The guidelines recommend 15-20 mg/kg based on actual body weight every 8-12 hours for normal renal function 1. For skin infections requiring lower troughs, the lower end of this range (15 mg/kg) is appropriate.

2. Normal renal function: With creatinine 0.7 mg/dL, this patient has excellent renal clearance, allowing for standard 12-hour intervals rather than extended intervals 2.

3. Infection type matters: The 2014 IDSA skin and soft tissue infection guidelines do not mandate the aggressive 15-20 mg/L trough targets that are reserved for invasive infections 3. Skin infections have better tissue penetration and lower bacterial burden than bacteremia or endocarditis.

Monitoring Considerations

For this skin infection case:

• Routine trough monitoring before the 4th dose is not necessary for short-course therapy (≤5 days) with lower-intensity dosing 1
• Consider monitoring only if:
  • Treatment extends beyond 5-7 days
  • Patient develops renal dysfunction
  • Concurrent nephrotoxic agents are used
  • Clinical response is inadequate

If monitoring is performed, target trough should be 10-15 mg/L (not 15-20 mg/L).

Important Caveats

When to Consider Higher Dosing (15-20 mg/L troughs):

Even for skin infections, escalate to higher-intensity dosing if:

• Complicated SSTI: Deep tissue involvement, necrotizing infection, or concern for bacteremia
• MRSA with MIC approaching 1-2 mg/L: Higher exposures needed for adequate AUC/MIC ratio 1
• Immunocompromised host: May require more aggressive therapy
• Clinical failure: Lack of improvement after 48-72 hours

Nephrotoxicity Risk

The lower dosing strategy for skin infections inherently reduces nephrotoxicity risk. The guidelines note that nephrotoxicity monitoring is "best suited for patients receiving aggressive dose targeting to produce sustained trough serum concentrations of 15-20 mg/L" 1—which does not apply to uncomplicated skin infections.

Practical Algorithm

Skin infection + 75 kg + Cr 0.7 mg/dL
↓
Uncomplicated SSTI?
├─ YES → 1000 mg IV q12h (target trough 10-15 mg/L)
│         No routine monitoring needed if <5 days
│
└─ NO (complicated/deep) → 1125-1500 mg IV q12h (target trough 15-20 mg/L)
                           Monitor trough before 4th dose

This approach balances efficacy for skin infections while minimizing unnecessary drug exposure and nephrotoxicity risk, which directly impacts patient morbidity and quality of life 1, 4.